BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 28012348)

  • 1. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
    Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
    Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
    Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.
    Chamberlain MC
    J Neurooncol; 2013 May; 113(1):27-32. PubMed ID: 23456654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
    Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and opportunities in primary CNS lymphoma: A systematic review.
    Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
    Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rare Case of Spontaneous Remission and Relapse of a Primary Central Nervous System Lymphoma.
    Ramos R; Fernandes JS; Almeida M; Almeida R
    Acta Med Port; 2018 Dec; 31(12):777-783. PubMed ID: 30684376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
    Provencher S; Ferlay C; Alaoui-Slimani K; Devidas A; Lepretre S; de Prijck B; Sebban C; de la Fouchardiere A; Chassagne-Clement C; Ketterer N; Thyss A; Delannoy A; Tilly H; Biron P; Blay JY; Ghesquières H
    Hematol Oncol; 2011 Mar; 29(1):10-6. PubMed ID: 21381074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
    Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
    J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.
    Ambady P; Fu R; Netto JP; Kersch C; Firkins J; Doolittle ND; Neuwelt EA
    Fluids Barriers CNS; 2017 Jun; 14(1):16. PubMed ID: 28577579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
    Harjama L; Kuitunen H; Turpeenniemi-Hujanen T; Haapasaari KM; Leppä S; Mannisto S; Karjalainen-Lindsberg ML; Lehtinen T; Eray M; Vornanen M; Haapasalo H; Soini Y; Jantunen E; Nousiainen T; Vasala K; Kuittinen O
    Acta Oncol; 2015 Jun; 54(6):939-43. PubMed ID: 25761092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
    Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
    J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
    Thompson CA; Ghesquieres H; Maurer MJ; Cerhan JR; Biron P; Ansell SM; Chassagne-Clément C; Inwards DJ; Gargi T; Johnston PB; Nicolas-Virelizier E; Macon WR; Peix M; Micallef IN; Sebban C; Nowakowski GS; Porrata LF; Weiner GJ; Witzig TE; Habermann TM; Link BK
    J Clin Oncol; 2014 Nov; 32(31):3506-12. PubMed ID: 25267745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Central Nervous System Lymphomas of the Brain: A Retrospective Analysis in a Single Institution.
    Lin TK; Yeh TH; Hsu PW; Chuang CC; Tu PH; Chen PY; Jung SM; Wei KC; Huang YC
    World Neurosurg; 2017 Jul; 103():550-556. PubMed ID: 28363832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.